These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical Applications of a Novel Selective PPARα Modulator, Pemafibrate, in Dyslipidemia and Metabolic Diseases. Yamashita S; Masuda D; Matsuzawa Y J Atheroscler Thromb; 2019 May; 26(5):389-402. PubMed ID: 30930344 [TBL] [Abstract][Full Text] [Related]
6. Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia. Yamashita S; Arai H; Yokote K; Araki E; Suganami H; Ishibashi S; J Clin Lipidol; 2018; 12(5):1267-1279.e4. PubMed ID: 30077640 [TBL] [Abstract][Full Text] [Related]
7. Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice. Iitake C; Iitake K J Clin Med Res; 2019 Oct; 11(10):690-695. PubMed ID: 31636783 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. Ishibashi S; Arai H; Yokote K; Araki E; Suganami H; Yamashita S; J Clin Lipidol; 2018; 12(1):173-184. PubMed ID: 29203092 [TBL] [Abstract][Full Text] [Related]
9. A Significant Increase of Estimated Glomerular Filtration Rate After Switching From Fenofibrate to Pemafibrate in Type 2 Diabetic Patients. Yanai H; Katsuyama H; Hakoshima M Cardiol Res; 2021 Dec; 12(6):358-362. PubMed ID: 34970366 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of K-877 (Pemafibrate), a Selective PPARα Modulator, in European Patients on Statin Therapy. Ginsberg HN; Hounslow NJ; Senko Y; Suganami H; Bogdanski P; Ceska R; Kalina A; Libis RA; Supryadkina TV; Hovingh GK Diabetes Care; 2022 Apr; 45(4):898-908. PubMed ID: 35238894 [TBL] [Abstract][Full Text] [Related]
11. Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis. Yamashita S; Rizzo M; Su TC; Masuda D Metabolites; 2023 May; 13(5):. PubMed ID: 37233667 [TBL] [Abstract][Full Text] [Related]
12. The novel selective PPARα modulator (SPPARMα) pemafibrate improves dyslipidemia, enhances reverse cholesterol transport and decreases inflammation and atherosclerosis. Hennuyer N; Duplan I; Paquet C; Vanhoutte J; Woitrain E; Touche V; Colin S; Vallez E; Lestavel S; Lefebvre P; Staels B Atherosclerosis; 2016 Jun; 249():200-8. PubMed ID: 27108950 [TBL] [Abstract][Full Text] [Related]
13. Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study. Kito K; Nomoto H; Sakuma I; Nakamura A; Cho KY; Kameda H; Miya A; Omori K; Yanagiya S; Handa T; Taneda S; Takeuchi J; Nagai S; Yamashita K; Kurihara Y; Atsumi T; Miyoshi H; Diabetes Res Clin Pract; 2022 Oct; 192():110091. PubMed ID: 36174777 [TBL] [Abstract][Full Text] [Related]
14. Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet. Yoshida M; Nakamura K; Miyoshi T; Yoshida M; Kondo M; Akazawa K; Kimura T; Ohtsuka H; Ohno Y; Miura D; Ito H Cardiovasc Diabetol; 2020 Sep; 19(1):149. PubMed ID: 32979918 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Low-Dose Pemafibrate Therapy for Hypertriglyceridemia in Patients with Type 2 Diabetes. Bando H; Taneda S; Manda N JMA J; 2021 Apr; 4(2):135-140. PubMed ID: 33997447 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Pemafibrate, a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator (SPPARMα): Pooled Analysis of Phase 2 and 3 Studies in Dyslipidemic Patients with or without Statin Combination. Yamashita S; Arai H; Yokote K; Araki E; Matsushita M; Nojima T; Suganami H; Ishibashi S Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31698825 [TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Pradhan AD; Paynter NP; Everett BM; Glynn RJ; Amarenco P; Elam M; Ginsberg H; Hiatt WR; Ishibashi S; Koenig W; Nordestgaard BG; Fruchart JC; Libby P; Ridker PM Am Heart J; 2018 Dec; 206():80-93. PubMed ID: 30342298 [TBL] [Abstract][Full Text] [Related]
18. Effects of a Novel Selective Peroxisome Proliferator-Activated Receptor α Modulator, Pemafibrate, on Metabolic Parameters: A Retrospective Longitudinal Study. Yanai H; Katsuyama H; Hakoshima M Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203610 [TBL] [Abstract][Full Text] [Related]
19. Clinical Efficacy and Safety of Low-Dose Pemafibrate in Patients With Severe Renal Impairment: A Retrospective Study. Shima H; Tashiro M; Inoue T; Okada K; Okamoto T; Wariishi S; Doi T; Minakuchi J Cureus; 2024 Apr; 16(4):e57777. PubMed ID: 38715994 [TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Ida S; Kaneko R; Murata K Cardiovasc Diabetol; 2019 Mar; 18(1):38. PubMed ID: 30898163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]